Drug
Telisotuzumab adizutecan clinical trials
Also written ABBV-400.
- studies test it
- 17
- open now
- 12
- in phase 3
- 5
- first study started
- 2021
Keep track of what changes. Save the telisotuzumab adizutecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
16 studies that test it; most in 2025 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 12
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Often tested with
Tested in the same studies.
Bevacizumab (3) · Leucovorin (1) · Fluorouracil (1) · Pembrolizumab (1) · Carboplatin (1) · Pemetrexed (1) · Cisplatin (1) · Oxaliplatin (1)
Studies
Open first, then newest update. How each study uses telisotuzumab adizutecan is read from its arms, and is right about nine times in ten.
Testing it · 17
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingPhase 1/2AbbVieNCT06772623Written as Telisotuzumab Adizutecan
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingPhase 2AbbVieNCT06820463Written as Telisotuzumab Adizutecan
- A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal CancerRecruitingPhase 3AbbVieNCT07525206Written as Telisotuzumab adizutecan
- A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2AbbVieNCT07744126Written as Telisotuzumab Adizutecan
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal AdenocarcinomaRecruitingPhase 2/3AbbVieNCT07490301Written as Telisotuzumab adizutecan
- A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary CancersRecruitingPhase 2AbbVieNCT07769502Written as Telisotuzumab Adizutecan
- A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of DiseaseRecruitingPhase 2AbbVieNCT07023289Written as Telisotuzumab Adizutecan
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerNot yet recruitingPhase 3AbbVieNCT07821684Written as Telisotuzumab Adizutecan
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3AbbVieNCT07005102Written as Telisotuzumab Adizutecan
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3AbbVieNCT07155187Written as Telisotuzumab Adizutecan
- A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab AdizutecanRecruitingPhase 2AbbVieNCT07196644Written as Telisotuzumab Adizutecan
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanRecruitingPhase 1AbbVieNCT05005403Written as Telisotuzumab Adizutecan
- A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal CancerActive, not recruitingPhase 2AbbVieNCT06614192Written as Telisotuzumab Adizutecan
- A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaActive, not recruitingPhase 2AbbVieNCT06628310Written as Telisotuzumab Adizutecan
- Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal CancerActive, not recruitingPhase 1AbbVieNCT06464692Written as Telisotuzumab Adizutecan
- Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabActive, not recruitingPhase 2AbbVieNCT06107413Written as ABBV-400
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV BevacizumabActive, not recruitingPhase 1AbbVieNCT05029882Written as ABBV-400
Given in every arm · 1 — telisotuzumab adizutecan is usual care beside what is tested
Codes
What other systems call telisotuzumab adizutecan · ClinicalTrials.gg INT016256
- UNII (FDA) CVX52RV2DCTELISOTUZUMAB ADIZUTECANOne source FDA
- NCI Thesaurus C184368Telisotuzumab AdizutecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CVX52RV2DC | TELISOTUZUMAB ADIZUTECAN | One source FDA |
| NCI Thesaurus | C184368 | Telisotuzumab Adizutecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.